Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership
Femasys Inc. (NASDAQ: FEMY) has announced a strategic partnership with Kebomed to commercialize its FemBloc Permanent Birth Control solution in France and Benelux countries. This partnership follows FemBloc's recent CE mark approval and targets France as the largest European market opportunity.
FemBloc is a revolutionary non-surgical permanent birth control solution that uses a proprietary polymer delivery system to create natural scar tissue in fallopian tubes. The technology eliminates risks associated with surgical sterilization, including anesthesia complications and infection, while offering a more cost-effective and accessible option for women.
Femasys Inc. (NASDAQ: FEMY) ha annunciato una partnership strategica con Kebomed per commercializzare la sua soluzione FemBloc Permanent Birth Control in Francia e nei paesi del Benelux. Questa partnership segue la recente approvazione del marchio CE di FemBloc e punta alla Francia come la maggiore opportunità di mercato europea.
FemBloc è una rivoluzionaria soluzione contraccettiva permanente non chirurgica che utilizza un sistema di rilascio polimerico proprietario per creare tessuto cicatriziale naturale nelle tube di Falloppio. La tecnologia elimina i rischi associati alla sterilizzazione chirurgica, inclusi complicazioni da anestesia e infezioni, offrendo al contempo un'opzione più economica e accessibile per le donne.
Femasys Inc. (NASDAQ: FEMY) ha anunciado una asociación estratégica con Kebomed para comercializar su solución FemBloc Permanent Birth Control en Francia y los países Benelux. Esta asociación se produce tras la reciente aprobación de la marca CE de FemBloc y tiene como objetivo Francia como la mayor oportunidad de mercado en Europa.
FemBloc es una revolucionaria solución permanente de control de la natalidad no quirúrgica que utiliza un sistema de liberación de polímero propio para crear tejido cicatricial natural en las trompas de Falopio. La tecnología elimina los riesgos asociados con la esterilización quirúrgica, incluyendo complicaciones de la anestesia e infecciones, al tiempo que ofrece una opción más rentable y accesible para las mujeres.
Femasys Inc. (NASDAQ: FEMY)는 프랑스와 벤엘릭스(Benelux) 국가에서 자사의 FemBloc Permanent Birth Control 솔루션을 상용화하기 위해 Kebomed와 전략적 파트너십을 발표했습니다. 이 파트너십은 최근 FemBloc의 CE 마크 승인을 따른 것으로, 프랑스를 유럽에서 가장 큰 시장 기회로 삼고 있습니다.
FemBloc는 독점적 폴리머 전달 시스템을 사용해 나팔관에 자연 흉터 조직을 형성하는 비수술적 영구 피임 솔루션으로, 전신 마취 합병증 및 감염을 포함한 수술적 불임의 위험을 제거하는 동시에 여성들에게 더 비용 효율적이고 접근 가능한 옵션을 제공합니다.
Femasys Inc. (NASDAQ: FEMY) a annoncé un partenariat stratégique avec Kebomed pour commercialiser sa solution FemBloc Permanent Birth Control en France et dans les pays du Benelux. Ce partenariat fait suite à l'approbation récente du marquage CE de FemBloc et vise la France comme la plus grande opportunité de marché en Europe.
FemBloc est une solution révolutionnaire non chirurgicale et permanente de contrôle des naissances qui utilise un système de délivrance polymère propriétaire pour créer un tissu cicatriciel naturel dans les trompes de Fallope. La technologie élimine les risques associés à la stérilisation chirurgicale, y compris les complications liées à l'anesthésie et les infections, tout en offrant une option plus économique et accessible pour les femmes.
Femasys Inc. (NASDAQ: FEMY) hat eine strategische Partnerschaft mit Kebomed angekündigt, um seine Lösung FemBloc Permanent Birth Control in Frankreich und den Benelux-Ländern zu kommerzialisieren. Diese Partnerschaft folgt der jüngsten CE-Zulassung für FemBloc und zielt darauf ab, Frankreich als größten europäischen Markt zu nutzen.
FemBloc ist eine revolutionäre nicht-chirurgische permanente Empfängnisverhütungs-Lösung, die ein proprietäres Polymerfreisetzungssystem verwendet, um natürliches Narbengewebe in den Eileitern zu erzeugen. Die Technologie eliminiert die mit chirurgischer Sterilisation verbundenen Risiken, einschließlich Anästhesiekomplikationen und Infektionen, und bietet gleichzeitig eine kosteneffizientere und zugängliche Option für Frauen.
Femasys Inc. (NASDAQ: FEMY) أعلنت عن شراكة استراتيجية مع Kebomed لتسويق حلاً FemBloc Permanent Birth Control في فرنسا ودول بنelux. تأتي هذه الشراكة عقب اعتماد FemBloc لشهادة CE مؤخرًا وتستهدف فرنسا كأكبر فرصة سوقية في أوروبا.
FemBloc هو حلاً غير جراحي دائم لمنع الحمل ثورة يستخدم نظام توصيل بوليمري مملوك لإنشاء نسيج ندبي طبيعي في قنوات فالوب. التكنولوجيا تقضي على المخاطر المرتبطة بالتعقيم الجراحي، بما في ذلك مضاعفات التخدير والعدوى، مع توفير خيار أكثر كفاءة من حيث التكلفة ومتاحة للنساء.
Femasys Inc. (NASDAQ: FEMY) 已宣布与Kebomed达成战略伙伴关系，在法国以及贝尼卢克斯地区商业化其FemBloc Permanent Birth Control解决方案。这一合作关系是在FemBloc最近获得CE认证之后签署的，目标将法国视为欧洲最大的市场机会。
FemBloc是一个革命性的非手术永久避孕解决方案，它使用专有聚合物释放系统在输卵管中创造自然瘢痕组织。这项技术消除了与外科绝育相关的风险，包括麻醉并发症和感染，同时为女性提供更具成本效益且更易获取的选择。
- Strategic partnership with Kebomed provides access to major European markets
- FemBloc is the only non-surgical permanent birth control option in the market
- Recent CE mark approval enables European commercialization
- Technology eliminates surgical risks and reduces healthcare costs
- France represents the largest single-market opportunity in Europe
- Market adoption and physician acceptance still needs to be proven
- Competition from established surgical sterilization methods may affect uptake
Insights
Femasys' partnership with Kebomed significantly expands FemBloc's market access in Europe's largest potential market following recent CE approval.
This strategic distribution partnership between Femasys and Kebomed represents a significant commercial milestone for FemBloc, the company's non-surgical permanent birth control solution. France constitutes the largest single-market opportunity for FemBloc in Europe, making this partnership particularly valuable following the product's recent CE mark approval.
The selection of Kebomed as a distribution partner is strategically sound given their established gynecology-focused portfolio and strong market presence across Europe. This partnership provides Femasys with immediate access to sophisticated distribution infrastructure in four key European markets without requiring substantial direct investment in sales operations.
From a competitive standpoint, FemBloc enjoys a unique position as a first-of-its-kind non-surgical permanent contraceptive with no comparable alternatives currently available. The product addresses significant limitations of surgical sterilization by eliminating anesthesia risks, infection possibilities, and recovery downtime—creating both clinical and economic advantages.
This partnership follows Femasys' methodical European expansion strategy, targeting high-value markets first following regulatory clearance. For investors, this represents accelerated commercialization in a major territory that could significantly impact near-term revenue potential while validating the product's market appeal through partnership with an established distributor.
The agreement specifically covers France, Netherlands, Belgium, and Luxembourg—representing sophisticated healthcare markets with strong gynecological practice infrastructure and favorable reimbursement environments for innovative women's health solutions.
-- Femasys leverages Kebomed’s pan-European distribution strength to drive adoption of FemBloc permanent birth control in France and Benelux, unlocking significant market access --
ATLANTA, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Kebomed, a leading European distributor of medical devices and equipment, to commercialize FemBloc Permanent Birth Control in France and the Benelux region (The Netherlands, Belgium, and Luxembourg). With France representing the largest single-market opportunity for FemBloc in Europe, this collaboration significantly expands access to the only non-surgical permanent birth control option and represents a major milestone in Femasys’ European growth strategy following recent CE mark approval.
“We are thrilled to partner with Kebomed, a leading distributor with deep expertise in women’s health and strong market access in key markets across Europe,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc. “France is a large market opportunity for FemBloc in the region, and Kebomed’s established infrastructure and gynecology-focused portfolio, make them the ideal partner to expand access, accelerate adoption, and unlock significant growth potential.”
Søren Dalmark Kornerup, Chairman of Kebomed Europe AG, stated, “FemBloc represents a revolutionary advancement in women’s health. With our strong presence in gynecology and established European network, we are well positioned to drive adoption in France and Benelux. Adding this permanent contraceptive solution further strengthens our women’s health portfolio and reinforces our leadership in this important field.”
FemBloc is a first-of-its-kind, non-surgical solution for permanent birth control, addressing a significant unmet need in women’s reproductive health. It uses a patented delivery system to place a proprietary blended polymer into both fallopian tubes, which safely degrades and forms natural scar tissue for permanent occlusion. In contrast to surgical sterilization, FemBloc eliminates the risks of anesthesia, infection, and recovery downtime, making it safer, more accessible, and significantly more cost-effective. With no comparable alternatives on the market, FemBloc represents a disruptive advancement with broad global potential. Learn more at www.FemBloc.com.
About Femasys
Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed® Intratubal Insemination, a groundbreaking first-step infertility treatment and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrates FemaSeed is over twice as effective as traditional IUI, with a comparable safety profile, and high patient and practitioner satisfaction.1
FemBloc® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June of 2025, the UK in August 2025, and New Zealand in September 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going.
Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
About Kebomed
Kebomed Europe AG is a leading independent distributor of medical devices with more than 30 years of heritage and a strong footprint across Europe. Founded in 1995 in Scandinavia, the company expanded through acquisitions in the UK, Benelux, Norway, followed by France, Switzerland, Germany, and Austria, establishing itself as one of the few truly pan-European platforms.
Women’s health has long been a strategic focus for Kebomed, supported by its close relationship with LiNA Medical, an innovator in minimally invasive gynecology owned by the same family. Through this connection, Kebomed distributes LiNA products in select European markets, strengthening its portfolio and reinforcing its leadership and deep clinical expertise in this important therapeutic area.
More information on Kebomed can be found at www.kebomed.com.
References
1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.
2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
David Gutierrez, Dresner Corporate Services, (312) 780-7204, dgutierrez@dresnerco.com
Nathan Abler, Dresner Corporate Services, (714) 742-4180, nabler@dresnerco.com
FAQ
What is the new partnership between Femasys (NASDAQ: FEMY) and Kebomed?
How does FemBloc permanent birth control work?
What are the advantages of FemBloc over traditional surgical sterilization?
When did Femasys receive CE mark approval for FemBloc?
Which European markets will Kebomed distribute FemBloc in?
